KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aurinia Pharmaceuticals (AUPH) Capital Expenditures (2018 - 2025)

Historic Capital Expenditures for Aurinia Pharmaceuticals (AUPH) over the last 10 years, with Q3 2025 value amounting to $65000.0.

  • Aurinia Pharmaceuticals' Capital Expenditures fell 2352.94% to $65000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $236000.0, marking a year-over-year decrease of 5496.18%. This contributed to the annual value of $281000.0 for FY2024, which is 6086.35% down from last year.
  • Per Aurinia Pharmaceuticals' latest filing, its Capital Expenditures stood at $65000.0 for Q3 2025, which was down 2352.94% from $98000.0 recorded in Q2 2025.
  • Over the past 5 years, Aurinia Pharmaceuticals' Capital Expenditures peaked at $1.0 million during Q1 2021, and registered a low of -$105000.0 during Q3 2023.
  • Moreover, its 5-year median value for Capital Expenditures was $82000.0 (2022), whereas its average is $156875.0.
  • As far as peak fluctuations go, Aurinia Pharmaceuticals' Capital Expenditures soared by 110813.95% in 2021, and later crashed by 36250.0% in 2023.
  • Over the past 5 years, Aurinia Pharmaceuticals' Capital Expenditures (Quarter) stood at $1.0 million in 2021, then crashed by 87.1% to $134000.0 in 2022, then surged by 123.13% to $299000.0 in 2023, then crashed by 81.27% to $56000.0 in 2024, then increased by 16.07% to $65000.0 in 2025.
  • Its Capital Expenditures was $65000.0 in Q3 2025, compared to $98000.0 in Q2 2025 and $17000.0 in Q1 2025.